Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 80 points (-0.5%) at 17,033 as of Monday, Sept. 29, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 959 issues advancing vs. 2,053 declining with 145 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is down 0.5%. A company within the industry that increased today was

Bristol-Myers Squibb Company

(

BMY

), up 1.1%. On the negative front, top decliners within the industry include

Seattle Genetics

(

SGEN

), down 6.1%,

Perrigo

(

PRGO

), down 1.3%,

AbbVie

(

ABBV

), down 1.2%,

Regeneron Pharmaceuticals

(

REGN

), down 1.1% and

Sanofi

(

SNY

), down 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Novo Nordisk A/S

(

NVO

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $0.29 (0.6%) to $48.41 on heavy volume. Thus far, 918,701 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 964,200 shares. The stock has ranged in price between $47.94-$48.58 after having opened the day at $48.01 as compared to the previous trading day's close of $48.12.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $131.4 billion and is part of the health care sector. Shares are up 30.2% year-to-date as of the close of trading on Friday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Novo Nordisk A/S

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Novo Nordisk A/S Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Valeant Pharmaceuticals International

(

VRX

) is up $1.23 (0.9%) to $130.22 on average volume. Thus far, 1.5 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $126.69-$131.85 after having opened the day at $127.64 as compared to the previous trading day's close of $128.99.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $42.9 billion and is part of the health care sector. Shares are up 9.9% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity. Get the full

Valeant Pharmaceuticals International Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Allergan

(

AGN

) is up $2.38 (1.3%) to $180.38 on average volume. Thus far, 886,289 shares of Allergan exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $175.57-$181.94 after having opened the day at $177.07 as compared to the previous trading day's close of $178.00.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $52.0 billion and is part of the health care sector. Shares are up 60.2% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Allergan

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Allergan Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null